Patents Assigned to Osiris Therapeutics, Inc.
-
Publication number: 20240408267Abstract: Disclosed are compositions and methods for treating wounds and damaged tissue using decidua tissue.Type: ApplicationFiled: September 29, 2022Publication date: December 12, 2024Applicant: OSIRIS THERAPEUTICS, INC.Inventors: Nasreen JACOBSON, Jin-Qiang KUANG, Min Sung PARK, Aleksa JOVANOVIC
-
Patent number: 12109241Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: January 6, 2023Date of Patent: October 8, 2024Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20240261335Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: April 11, 2024Publication date: August 8, 2024Applicant: Osiris Therapeutics, Inc.Inventors: Timothy JANSEN, Samson TOM, Alla DANILKOVITCH, Dana YOO, Jaime ZERHUSEN
-
Publication number: 20240189361Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: February 22, 2024Publication date: June 13, 2024Applicant: OSIRIS THERAPEUTICS, INC.Inventors: Samson TOM, Alla DANILKOVITCH, Dana YOO, Timothy JANSEN, Jin-Qiang KUANG, Jennifer Michelle MARCONI
-
Publication number: 20240189362Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: February 22, 2024Publication date: June 13, 2024Applicant: OSIRIS THERAPEUTICS, INC.Inventors: Samson TOM, Alla DANILKOVITCH, Dana YOO, Timothy JANSEN, Jin-Qiang KUANG, Jennifer Michelle MARCONI
-
Patent number: 11986498Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: October 17, 2013Date of Patent: May 21, 2024Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Timothy Jansen, Samson Tom, Alla Danilkovitch, Dana Yoo, Jaime Zerhusen
-
Patent number: 11638725Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: February 8, 2019Date of Patent: May 2, 2023Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 11590173Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: April 6, 2020Date of Patent: February 28, 2023Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 11590172Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: March 8, 2019Date of Patent: February 28, 2023Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana YOo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20230047934Abstract: Disclosed are compositions comprising a minced chorionic matrix, a homogenized amniotic matrix, and a homogenized umbilical cord (UC) matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising isolated, viable chorionic cells, a homogenized amniotic matrix, and a homogenized UC matrix, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising a minced chorionic matrix and a homogenized UC matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts or an amniotic matrix. Disclosed are compositions comprising isolated, viable chorionic cells and a homogenized UC matrix, wherein the composition does not comprise trophoblasts or an amniotic matrix.Type: ApplicationFiled: March 12, 2021Publication date: February 16, 2023Applicant: Osiris Therapeutics, Inc.Inventors: Steven Michael SINCLAIR, Alla DANILKOVITCH, Malathi SATHYAMOORTHY, Jin-Qiang KUANG, Sandeep DHALL, Yishan LIU, Anthony John MELCHIORRI, Matthew Robert MOORMAN, Mena Schiano LO MORIELLO, Anne Allgood LERCH
-
Patent number: 11510947Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: January 7, 2020Date of Patent: November 29, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 11464809Abstract: Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.Type: GrantFiled: April 6, 2020Date of Patent: October 11, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Alla Danilkovitch, Yi Duan-Arnold, Matthew Moorman, Anne Lerch, Jin-Qiang Kuang
-
Patent number: 11413373Abstract: This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.Type: GrantFiled: September 26, 2014Date of Patent: August 16, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Dana Sue Yoo, Jin-Qiang Kuang, Jaime Paden, Scott A. Maxson, Alla Danilkovitch, Erasmo Lopez, Samson Tom
-
Patent number: 11406735Abstract: This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.Type: GrantFiled: September 12, 2014Date of Patent: August 9, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Dana Sue Yoo, Jin-Qiang Kuang, Jaime Paden, Scott A. Maxson, Alla Danilkovitch, Erasmo Lopez, Samson Tom
-
Patent number: 11318168Abstract: Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non-homogenized chorionic matrix comprises viable cells. Disclosed are methods of making the compositions disclosed herein comprising preparing a non-homogenized chorionic matrix, preparing a homogenized amniotic matrix, preparing a homogenized UC matrix, and combining the non-homogenized chorionic matrix, the non-homogenized chorionic matrix, and the homogenized UC matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.Type: GrantFiled: June 23, 2017Date of Patent: May 3, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Steven Michael Sinclair, Alla Danilkovitch, Malathi Sathyamoorthy, Jin-Qiang Kuang, Sandeep Dhall, Yishan Liu, Anthony John Melchiorri, Matthew Robert Moorman, Mena Schiano Lo Moriello, Anne Allgood Lerch
-
Patent number: 11207353Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: March 8, 2019Date of Patent: December 28, 2021Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 10994913Abstract: A support assembly for supporting a biological product (e.g., membrane) in an operative position. The support assembly has a base and a cover. A membrane receiving portion of the base defines a plurality of perforations that extend between top and bottom surfaces of the product receiving portion. The cover is releasably coupled to the base in a product-covering position in which the cover overlies the product receiving portion of the base. In the operative position, the biological product engages the top surface of the product receiving portion and the bottom surface of the cover.Type: GrantFiled: February 19, 2019Date of Patent: May 4, 2021Assignee: Osiris Therapeutics, Inc.Inventors: Yi Duan-Arnold, Alla Danilkovitch, Alexandra Gyurdieva, Jin-Qiang Kuang, Steven Michael Sinclair
-
Publication number: 20210023268Abstract: Provided herein is a bone repair composition that is composed of periosteum containing an angiogenic growth factor(s), cancellous bone chips containing viable osteogenic cells, and, optionally, demineralized bone matrix (DBM) chips. Also provided herein are articles of manufacture and methods of use thereof to treat bone defects.Type: ApplicationFiled: September 30, 2020Publication date: January 28, 2021Applicant: Osiris Therapeutics, Inc.Inventors: Thomas E. UVEGES, Jin-Qiang KUANG, Alla DANILKOVITCH, S. Michael SINCLAIR, Sandra D. GERAGHTY
-
Patent number: 10874763Abstract: This invention provides porated cartilage products, methods of producing porated cartilage products, and methods of treating subjects by administering cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.Type: GrantFiled: August 20, 2014Date of Patent: December 29, 2020Assignee: Osiris Therapeutics, Inc.Inventors: Dana Yoo, Jin-Qiang Kuang, Jaime Paden, Scott Maxson, Alla Danilkovitch, Erasmo Lopez, Samson Tom
-
Patent number: 10828395Abstract: Provided herein is a bone repair composition that is composed of periosteum containing an angiogenic growth factor(s), cancellous bone chips containing viable osteogenic cells, and, optionally, demineralized bone matrix (DBM) chips. Also provided herein are articles of manufacture and methods of use thereof to treat bone defects.Type: GrantFiled: October 19, 2016Date of Patent: November 10, 2020Assignee: Osiris Therapeutics, Inc.Inventors: Thomas E. Uveges, Jin-Qiang Kuang, Alla Danilkovitch, S. Michael Sinclair, Sandra D. Geraghty